ClinicalTrials.gg
Active, not recruitingNCT05565378Updated Nov 9, 2026

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

A Phase 2 interventional study of Pembrolizumab and Dostarlimab in Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline. Active, not recruiting at 99 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Updated Nov 9, 2026Primary completion moved12 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
351
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline — 1 open to participants now, 7 under way, 3 of them phase 3. Carcinoma, Non-Small-Cell Lung · GlaxoSmithKline.

Enrollment
11th of 47
351 · median 88
Started
2022
with 1 other
Phase 2
18 of 54
none open now
Registered
49th of 54
by date

Among the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, this one is the 11th largest by enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2022, is one of 18 in phase 2, and was the 49th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] >= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.

03

Conditions studied

  • Lung Cancer, Non-Small Cell

Keywords

  • Belrestotug
  • Dostarlimab
  • EOS884448
  • GSK6097608
  • GSK4428859A
  • Nelistotug
  • Non-small-cell lung cancer
  • Pembrolizumab
  • Programmed death ligand 1
  • Programmed death protein 1 Inhibitor
  • Immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or NSCLC (squamous or non squamous)
  • No prior systemic therapy for their locally advanced or metastatic NSCLC
  • Provides a fresh tumor tissue sample or collected within 2 years prior to screening
  • -high (TC/TPS >= 50%) tumor
  • based on 1.1, as determined by the investigator
  • (ECOG) Performance Status score of 0 or 1
  • Adequate Baseline organ function
  • Female participants of must use adequate

Exclusion criteria

Exclusion Criteria:

  • Has NSCLC with a tumor that harbors any of the following molecular alterations: EGFR and /or ALK translocations mutations that are sensitive to available targeted inhibitor therapy, Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for treatment of locally advanced or NSCLC.
  • Had major surgery within 4 weeks or lung radiation of >30 Gy therapy within 6 months prior to the first dose of study intervention
  • Received prior therapy with any
  • Never smoked, defined as smoking \<100 tobacco cigarettes in a lifetime
  • Has an invasive or history of invasive malignancy other than the disease under study within the last 5 years (clinical exceptions apply as per protocol)
  • Symptomatic, untreated, or actively progressing, or any (regardless of symptomatology, treatment status, or stability)
  • disease or syndrome that required systemic treatment within the past 2 years
  • Receiving systemic therapy \<= 3 days prior to first dose of study intervention or any form of medication
  • Received any \<= 30 days prior to first dose of study intervention
  • Any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis
  • History or evidence of cardiac abnormalities
  • Current unstable liver or biliary disease
  • Severe infection within 4 weeks prior to the first dose of study intervention
  • Positive for tuberculosis, (HIV) infection, surface antigen, or
  • Has advanced, symptomatic, or visceral spread and is considered to be at imminent risk of life-threatening complications (including, but not limited to, massive uncontrolled effusions [e.g., pleural, pericardial, peritoneal])
  • Is currently participating in or has participated in a study of an therapy within 4 weeks prior to the first dose of study intervention
  • Has a history of allogeneic tissue/stem cell transplant or solid organ transplant
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
351 participants (actual)

Study arms

  • Active comparator
    Pembrolizumab Monotherapy

    Participants will be administered with pembrolizumab as monotherapy in a fixed dose.

    Drug: Pembrolizumab

  • Experimental
    Dostarlimab Monotherapy

    Participants will be administered with dostarlimab as monotherapy in a fixed dose.

    Drug: Dostarlimab

  • Experimental
    Substudy 1A

    Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose A).

    Drug: Dostarlimab · Drug: Belrestotug

  • Experimental
    Substudy 1B

    Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose B).

    Drug: Dostarlimab · Drug: Belrestotug

  • Experimental
    Substudy 1C

    Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose C).

    Drug: Dostarlimab · Drug: Belrestotug

  • Experimental
    Substudy 2A

    Participants will be administered with dostarlimab, fixed dose belrestotug, and fixed dose nelistotug

    Drug: Dostarlimab · Drug: Belrestotug · Drug: Nelistotug

Interventions

  • Pembrolizumab will be administered.

  • Dostarlimab will be administered

    Also known as: GSK4057190

  • Belrestotug will be administered.

    Also known as: EOS884448, GSK4428859A

  • Nelistotug will be administered.

    Also known as: GSK6097608

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to 228 weeks

  2. Number of Participants with TEAEs or SAEs leading to dose modifications or treatment discontinuation

    Time frame: Up to 228 weeks

07

Study locations

99 sites
  • GSK Investigational Site
    Plantation, Florida 33322-5426, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87131, United States
  • GSK Investigational Site
    Chattanooga, Tennessee 37404, United States
  • GSK Investigational Site
    Morgantown, West Virginia 26506, United States
  • GSK Investigational Site
    Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Cipoletti Rio Negro, R8324CVE, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aire, C1414DRK, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aire, C1426AGE, Argentina
  • GSK Investigational Site
    Florida, 1602, Argentina
  • GSK Investigational Site
    Mar del Plata, 7600, Argentina
  • GSK Investigational Site
    San Juan, J5402DIL, Argentina
  • GSK Investigational Site
    Santa Fe, 3000, Argentina
  • GSK Investigational Site
    Wilrijk, 2650, Belgium
  • GSK Investigational Site
    Barretos, 14784-400, Brazil
  • GSK Investigational Site
    Porto Alegre, 90610-000, Brazil
  • GSK Investigational Site
    São Paulo, 01246-000, Brazil
  • GSK Investigational Site
    Vitória, 29043-260, Brazil
  • GSK Investigational Site
    Oulu, 90220, Finland
  • GSK Investigational Site
    Tampere, 33520, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Vaasa, 65130, Finland
  • GSK Investigational Site
    Bordeaux, 33076, France
  • GSK Investigational Site
    Caen, 14033, France
  • GSK Investigational Site
    Marseille, 13009, France
  • GSK Investigational Site
    Quimper, 29107, France
  • GSK Investigational Site
    Strasbourg, 67091, France
  • GSK Investigational Site
    Essen, North Rhine-Westphalia 45147, Germany
  • GSK Investigational Site
    Großhansdorf, Schleswig-Holstein 22927, Germany
  • GSK Investigational Site
    Jena, Thuringia 07747, Germany
  • GSK Investigational Site
    Berlin, 13125, Germany
  • GSK Investigational Site
    Heidelberg, 69126, Germany
  • GSK Investigational Site
    Athens, Attica 115 27, Greece
  • GSK Investigational Site
    Chaïdári, Attica 124 62, Greece
  • GSK Investigational Site
    Thessaloniki, Central Macedonia 570 10, Greece
  • GSK Investigational Site
    Larissa, Thessaly 411 10, Greece
  • GSK Investigational Site
    Athens, 11528, Greece
  • GSK Investigational Site
    Pylaia Thessaloniki, 57001, Greece
  • GSK Investigational Site
    Thessaloniki, 54645, Greece
  • GSK Investigational Site
    Budapest, H-1121, Hungary
  • GSK Investigational Site
    Gyöngyös, 3200, Hungary
  • GSK Investigational Site
    Tatabánya, 2800, Hungary
  • GSK Investigational Site
    Genova, GE 16132, Italy
  • GSK Investigational Site
    Avellino, 83100, Italy
  • GSK Investigational Site
    Bergamo, 24125, Italy
  • GSK Investigational Site
    Pisa, 57124, Italy
  • GSK Investigational Site
    Verona, 37045, Italy
  • GSK Investigational Site
    Chiba, 277-8577, Japan
  • GSK Investigational Site
    Fukuoka, 812-8582, Japan
  • GSK Investigational Site
    Hyōgo, 673-8558, Japan
  • GSK Investigational Site
    Kanagawa, 241-8515, Japan
  • GSK Investigational Site
    Osaka, 590-0197, Japan
  • GSK Investigational Site
    Saitama, 350-1298, Japan
  • GSK Investigational Site
    Guadajalara, 44280, Mexico
  • GSK Investigational Site
    San Luis Potosí City, 78209, Mexico
  • GSK Investigational Site
    Enschede, 7512 KZ, Netherlands
  • GSK Investigational Site
    Groningen, 9728 NZ, Netherlands
  • GSK Investigational Site
    Leeuwarden, 8934 AD, Netherlands
  • GSK Investigational Site
    Utrecht, 3543 AZ, Netherlands
  • GSK Investigational Site
    Lublin, 20-954, Poland
  • GSK Investigational Site
    Prabuty, 82-550, Poland
  • GSK Investigational Site
    Siedlce, 08-110, Poland
  • GSK Investigational Site
    Guimarães, 4835-044, Portugal
  • GSK Investigational Site
    Lisbon, 1500-650, Portugal
  • GSK Investigational Site
    Lisbon, 1998-018, Portugal
  • GSK Investigational Site
    Porto, 4200-072, Portugal
  • GSK Investigational Site
    Vila Nova de Gaia, 4434-502, Portugal
  • GSK Investigational Site
    Cape Town, 7570, South Africa
  • GSK Investigational Site
    Parktown, 2193, South Africa
  • GSK Investigational Site
    Incheon, 21565, South Korea
  • GSK Investigational Site
    Seoul, 03080, South Korea
  • GSK Investigational Site
    Seoul, 03722, South Korea
  • GSK Investigational Site
    Suwon Gyeonggi-do, 442-723, South Korea
  • GSK Investigational Site
    Badalona, Barcelona 08916, Spain
  • GSK Investigational Site
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • GSK Investigational Site
    Badajoz, 06080, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Las Palmas de Gran Canar, 35016, Spain
  • GSK Investigational Site
    Madrid, 28027, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Málaga, 29010, Spain
  • GSK Investigational Site
    PamplonaNavarra, 28027, Spain
  • GSK Investigational Site
    Valencia, 46009, Spain
  • GSK Investigational Site
    Valencia, 46026, Spain
  • GSK Investigational Site
    Bangkok, 10210, Thailand
  • GSK Investigational Site
    Chiang Mai, 50200, Thailand
  • GSK Investigational Site
    Kho Hong Hat Yai, 90110, Thailand
  • GSK Investigational Site
    Khon Kaen, 40002, Thailand
  • GSK Investigational Site
    Pathum Thani, 12120, Thailand
  • GSK Investigational Site
    Samsun, Atakum 55200, Turkey (Türkiye)
  • GSK Investigational Site
    Ankara, 06680, Turkey (Türkiye)
  • GSK Investigational Site
    Ankara, 06800, Turkey (Türkiye)
  • GSK Investigational Site
    Antalya, 07070, Turkey (Türkiye)
  • GSK Investigational Site
    Istanbul, 34214, Turkey (Türkiye)
  • GSK Investigational Site
    Abu Dhabi, 51900, United Arab Emirates
  • GSK Investigational Site
    Abu Dhabi, United Arab Emirates
  • GSK Investigational Site
    Northwood, Middlesex HA6 2RN, United Kingdom
  • GSK Investigational Site
    Middlesbrough, TS4 3BW, United Kingdom
  • GSK Investigational Site
    Wolverhampton, WV10 0QP, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Oct 2026, 48 months.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 48 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2022
First posted
Oct 4, 2022
StartActual
Oct 14, 2022
Primary completionActual
Oct 26, 2026was Nov 2026
CompletionEst.
Dec 6, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added, 12 sites removed
Show 12 added (4 Greece, 3 Germany, 2 Spain, 1 Italy, 1 Portugal, 1 United Kingdom)
  • GSK Investigational Site · Essen, Germany
  • GSK Investigational Site · Großhansdorf, Germany
  • GSK Investigational Site · Jena, Germany
  • GSK Investigational Site · Athens, Greece
  • GSK Investigational Site · Chaïdári, Greece
  • GSK Investigational Site · Thessaloniki, Greece
  • GSK Investigational Site · Larissa, Greece
  • GSK Investigational Site · Genova, Italy
  • GSK Investigational Site · Vila Nova de Gaia, Portugal
  • GSK Investigational Site · Badalona, Spain
  • GSK Investigational Site · L'Hospitalet de Llobregat, Spain
  • GSK Investigational Site · Northwood, United Kingdom
Show 12 removed
  • GSK Investigational Site · Essen, Germany
  • GSK Investigational Site · Großhansdorf, Germany
  • GSK Investigational Site · Jena, Germany
  • GSK Investigational Site · Haidari - Athens, Greece
  • GSK Investigational Site · Larissa, Greece
  • GSK Investigational Site · PapagosAthens, Greece
  • GSK Investigational Site · Thessaloniki, Greece
  • GSK Investigational Site · Genova, Italy
  • GSK Investigational Site · Gaia, Portugal
  • GSK Investigational Site · Badalona, Spain
  • GSK Investigational Site · Barcelona, Spain
  • GSK Investigational Site · Middlesex, United Kingdom
Nov 9, 2026
Primary completion
Nov 9, 2026→Oct 26, 2026 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    12 sites added, 12 sites removed
    Show 12 added (4 Greece, 3 Germany, 2 Spain, 1 Italy, 1 Portugal, 1 United Kingdom)
    • GSK Investigational Site · Essen, Germany
    • GSK Investigational Site · Großhansdorf, Germany
    • GSK Investigational Site · Jena, Germany
    • GSK Investigational Site · Athens, Greece
    • GSK Investigational Site · Chaïdári, Greece
    • GSK Investigational Site · Thessaloniki, Greece
    • GSK Investigational Site · Larissa, Greece
    • GSK Investigational Site · Genova, Italy
    • GSK Investigational Site · Vila Nova de Gaia, Portugal
    • GSK Investigational Site · Badalona, Spain
    • GSK Investigational Site · L'Hospitalet de Llobregat, Spain
    • GSK Investigational Site · Northwood, United Kingdom
    Show 12 removed
    • GSK Investigational Site · Essen, Germany
    • GSK Investigational Site · Großhansdorf, Germany
    • GSK Investigational Site · Jena, Germany
    • GSK Investigational Site · Haidari - Athens, Greece
    • GSK Investigational Site · Larissa, Greece
    • GSK Investigational Site · PapagosAthens, Greece
    • GSK Investigational Site · Thessaloniki, Greece
    • GSK Investigational Site · Genova, Italy
    • GSK Investigational Site · Gaia, Portugal
    • GSK Investigational Site · Badalona, Spain
    • GSK Investigational Site · Barcelona, Spain
    • GSK Investigational Site · Middlesex, United Kingdom
    Primary completion Nov 9, 2026→Oct 26, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05565378
Lead sponsor
GlaxoSmithKline
Collaborators
iTeos Therapeutics
Responsible party
Sponsor
First posted
Oct 4, 2022
Start date
Oct 14, 2022
Primary completion
Oct 26, 2026
Completion
Dec 6, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Belrestotug · Nelistotug

Start the discussion